Pulse Biosciences rises as FDA greenlights co's study on cardiac device

Pulse Biosciences

27/11/2023 18:40

** Shares of Pulse Biosciences  PLSE.O  rise as much as
19.7% to a near 4-month high of $8.70; last up 14.7% in
afternoon trade
    ** Co says it has received all regulatory approvals to start
a small study on its cardiac device
    ** PLSE expects to provide updates from the study on the
device CellFX nsPFA Cardiac Catheter by January-end 
    ** Co will submit an application to FDA for clearance of
another medical device CellFX nsPFA cardiac clamp for surgery to
U.S. FDA by January-end as well
    ** Including session's gain, stock has more than tripled YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))